486 filings
Page 2 of 25
6-K
qdnicl3xct82 xmtas
22 Nov 23
Report of Foreign Private Issuer
4:30pm
6-K
to3sfjalttqafc3l2p15
21 Nov 23
Report of Foreign Private Issuer
8:00am
6-K
07duw5cc
31 Oct 23
Report of Foreign Private Issuer
4:30pm
6-K
l3lm7nmczjrdrf7s
4 Oct 23
Notice of the Special General Meeting of Shareholders
9:00am
6-K
i07n lpidx40s
12 Sep 23
Report of Foreign Private Issuer
7:30am
6-K/A
udq7dc4
21 Aug 23
Current report (foreign) (amended)
7:31am
6-K
6uf2 u6x46o64dwu2
28 Jul 23
Current Report
7:00am
6-K
quw25o
26 Jul 23
Report of Foreign Private Issuer
9:00am
6-K
xgx01pqqiyh60lb95vt
11 Jul 23
Altamira Therapeutics Announces Pricing of $5.0 Million Public Offering
8:32am
424B4
6zxvahmb1y3u7 apcml
7 Jul 23
Prospectus supplement with pricing info
4:14pm
EFFECT
pkje2cyr 51ri4g3
6 Jul 23
Notice of effectiveness
12:15am
CORRESP
fw60rcn
5 Jul 23
Correspondence with SEC
12:00am
CORRESP
gcxx2ed
5 Jul 23
Correspondence with SEC
12:00am
6-K
ewep sfni36
3 Jul 23
Report of Foreign Private Issuer
7:11pm
F-1/A
utg8v9 68
3 Jul 23
Registration statement (foreign) (amended)
7:09pm
6-K
awtn 2dmaag51rx21ipu
30 Jun 23
Report of Foreign Private Issuer
6:30am
6-K
5kzohdx6
27 Jun 23
Current Report
4:45pm
UPLOAD
mzqw lesrioouni89q
23 Jun 23
Letter from SEC
12:00am
F-1
e05g 4bpd7lreoq8
16 Jun 23
Registration statement (foreign)
5:01pm
6-K
g9gt8p6t85ffo14zn9b
15 Jun 23
Altamira Therapeutics Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular Syndrome
4:30pm